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ABSTRACT 
Knowledge of the plasma selenium levels associated with optimised concentration or activity 
of specific selenoproteins can provide considerable insights from epidemiological data on the 
possible involvement of those selenoproteins in health, most notably with respect to cancer.  
For cohort studies, if selenoproteins such as glutathione peroxidase and selenoprotein P are 
relevant to cancer, one might only expect to see an effect on risk when the concentrations in 
the cohort range from below, to above, the level needed to optimise the activity of these 
enzymes.  Similarly, trials would only show a beneficial effect of supplementation if 
selenium status were raised from below, to above, the optimal concentration for the 
selenoproteins likely to be implicated in cancer risk, as occurred in the NPC trial but not in 
SELECT.  The most powerful evidence for the involvement of selenoproteins in human 
health comes from epidemiological studies that have related single nucleotide polymorphisms 
in selenoproteins to disease risk.  The totality of the evidence currently implicates GPx1, 
GPx4, SEPS1, Sep15, SEPP1 and TXNRD1 in conditions such as cardiovascular disease, 
pre-eclampsia and cancer.  Future studies therefore need to determine not only selenium 
status, but genotype, both in selenoproteins and related pathways, when investigating the 
relationship of selenium with disease risk.   
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INTRODUCTION 
Only a small proportion of studies that can properly be described as epidemiological give any 
information about the role of selenoproteins in human health.  The biggest group consists of 
those studies that have identified an effect of a single nucleotide polymorphism (SNP) in a 
selenoprotein and related it to disease risk.  The number of such studies is increasing and, 
funding permitting, in the future we shall be able to run substantial interventions in subjects 
recruited by selenoprotein genotype.  Though the link is less specific, knowledge of the 
plasma levels associated with optimised concentration or activity of specific selenoproteins 
can provide considerable insights from published epidemiological data on possible 
involvement of those selenoproteins in health, most notably with respect to cancer.  From 
studies currently being conducted by Burk’s group in China, we should soon know what 
intake and plasma level of selenium (Se) are associated with maximal selenoprotein P 
concentration (Burk, R.F., personal communication).  This will help tremendously in 
assessing the importance of selenoprotein P, the carrier of Se to the tissues, to human health.  
 Addressing specific health conditions in turn, I will present the evidence for 
involvement of the selenoproteins from the various strands outlined above. 
 
 
CARDIOVASCULAR DISEASE 
Glutathione peroxidase (GPx) 
Previous epidemiological studies of Se and cardiovascular disease that did not include a 
substantial number of subjects of low or fairly low Se status were unable to find an effect on 
cardiovascular disease risk [1].  Such results point to a potential involvement of a 
selenoenzyme that is optimized at relatively low Se status, the most obvious candidate being 
the cytosolic selenoprotein, GPx1 [2,3,4].   
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 It was therefore revealing to find a later study in a population of relatively low Se 
status where the risk of having a cardiovascular event was examined according to baseline 
GPx1 activity.  Blankenberg and colleagues conducted a prospective study in a German 
population of 636 patients with suspected coronary artery disease, following them up for a 
median period of 4.7 years [4].  Mean plasma selenium was 69.5 and 74.5 µg/L at baseline in 
patients with and without an event, respectively.  Baseline erythrocyte GPx1 activity was a 
strong predictor of the risk of a subsequent cardiovascular event, those in the highest,  
compared to the lowest quartile of GPx1 activity having a hazard ratio (HR) of 0.29 [95% 
confidence interval (CI) 0.15 to 0.58; P<0.001].  The inverse association between GPx1 
activity and cardiovascular events remained substantially unchanged after adjustment for 
potential confounders showing that the relationship was independent of other cardiovascular 
risk factors.  Unsurprisingly perhaps, higher GPx1 activity was even more protective in 
smokers who are subject to greater oxidative stress than non-smokers.  Though it was 
erythrocyte GPx that was measured, the authors comment that erythrocyte GPx1 is probably a 
surrogate for cellular GPx1 activity in general.  Such an effect was able to be seen in this 
population because Se status was too low for GPx1 activity to be optimized in all subjects 
[5].   
 
 
Selenoprotein S (SEPS1)  
Inflammation in the arterial wall is recognized to be an important component of the 
development of acute coronary syndromes [6].  The selenoprotein SEPS1 has a role in 
mediating inflammation through its protection of the endoplasmic reticulum (ER).  SEPS1 is 
an ER membrane protein that participates in the processing and removal of misfolded 
proteins from the ER to the cytosol [7].  When the ER is functionally impaired by the build-
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up of such misfolded proteins, the expression of a number of genes is induced leading to 
activation of the transcription factor NF-κB.  Activated NF-κB then translocates to the 
nucleus where it activates the transcription of genes including those that encode the pro-
inflammatory cytokines [7] and indeed SEPS1 itself [8].  Increased expression of SEPS1 in 
turn suppresses cytokine production by its ability to remove misfolded proteins from the ER.  
This system constitutes a SEPS1-dependent regulatory loop in the presence of inflammation 
[8].  Variation in the SEPS1 gene is known to affect circulating levels of the inflammatory 
cytokines interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor alpha 
(TNF-α) [7].   
 Given the known association of SEPS1 with inflammation, the effect of genetic 
polymorphisms in SEPS1 on the risk of cardiovascular disease was investigated in two 
independent prospective Finnish cohorts [9].  A significant association was found with 
increased coronary heart disease risk in females carrying the minor allele of rs8025174 in the 
combined analysis of both cohorts (HR 2.95; 95% CI 1.37 to 6.39).  Another variant, 
rs7178239, increased the risk for ischemic stroke significantly in females (HR 3.35; 95% CI 
1.66–6.76) and in the joint analysis of both sexes in both cohorts (HR 1.75; 95% CI 1.17 to 
2.64). Suggestive associations of both variants were also seen with the known cardiovascular 
risk factors of BMI and waist-hip ratio [9].  These results implicate the selenoprotein SEPS1 
in cardiovascular disease risk, particularly in females.   
 
 
PRE-ECLAMPSIA 
Selenoprotein S (SEPS1)  
The pregnancy condition, pre-eclampsia, bears many similarities to cardiovascular disease 
and is associated with a considerably higher risk of developing vascular and metabolic 
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disease later in life [10].  The well-recognised endothelial dysfunction of pre-eclampsia is 
now believed to be part of a more generalised intravascular inflammatory reaction resulting 
from an excessive maternal inflammatory response to pregnancy [11].  High circulating 
levels of pro-inflammatory cytokines and other markers of inflammation including C-reactive 
protein have been reported in women with pre-eclampsia [12,13].    
 As with cardiovascular disease, the anti-inflammatory selenoprotein, SEPS1, is also 
implicated in the risk of pre-eclampsia [12].  Apart from the obvious link to inflammation, 
ER stress is also present in pre-eclampsia as a result of the ischaemia-reperfusion injury, a 
known cause of ER stress, that occurs in the pre-eclamptic placenta [12].   
 In a large case-control association study in a Norwegian population, Moses and 
colleagues [12] showed an association between a functional promoter polymorphism 
associated with impaired expression of SEPS1 and pre-eclampsia.  Maternal genotype and 
allele frequencies of the SEPS1 g.-105G>A polymorphism were compared in 1139 pre-
eclamptic and 2269 control women.  Women with preeclampsia were 1.34 times more likely 
to have the GA or AA genotype [P = 0.0039; odds ratio (OR), 1.34, 95% CI 1.09 to 1.64] and 
1.22 times more likely to carry the A allele (P = 0.023; OR 1.22, 95% CI 1.02 to 1.46).  
Importantly, the A allele of the SEPS1 g.-105G>A polymorphism is associated with impaired 
expression of SEPS1 and may therefore be contributing to pre-eclampsia risk.   
 This polymorphism is not currently in the SNP database but it is distinct from those 
(rs8025174 and rs7178239) mentioned above that were shown to have a relationship with 
cardiovascular disease.   
 
 
CANCER 
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There has been fairly general acceptance that a Se metabolite, methyl selenol, is a proximal 
anti-carcinogen at supra-nutritional doses [14].  However the presence of methyl selenol is 
only inferred from reactions of its precursors, most notably the model compound, 
methylseleninic acid [15].  Furthermore for this mechanism to be effective, Se doses large 
enough to support the production of high, steady-state concentrations of methyl selenol are 
likely to be required.  Despite the fact that such concentrations of methyl selenol should have 
been attained in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) where men 
of good Se status (mean baseline serum Se 136 µg/L) were given a further 200 µg Se/d, there 
was notably no effect of Se supplementation on prostate-cancer risk [16]. 
 Though selenoproteins (selenoenzymes) were known to reduce oxidative stress and 
inflammation and limit DNA damage, all of which have been implicated in cancer risk, they 
were at one time not thought to be important to the anti-cancer effects of Se.  This was 
largely because their activity/concentration was already believed to be optimized in the US 
population that showed reduced cancer risk on supplementation with 200 µg Se/d in the 
Nutritional Prevention of Cancer (NPC) Trial [17].  However, we now believe that optimal 
expression of selenoprotein P, the carrier of Se in the plasma, would almost certainly not 
have been achieved in all study subjects [18], particularly not in those in the bottom tertile of 
plasma Se (≤ 106 µg/L) in whom Se supplementation had the greatest benefit [19].  We are 
now also aware that people differ substantially in their ability to increase selenoprotein 
expression and activity in response to additional dietary Se so that some individuals may have 
a higher than average requirement for Se for optimal protection against cancer [20–24].  
 Though the use of animal models including transgenes for unique tRNA species has 
helped to clarify the relative contributions of Se metabolites and individual selenoproteins to 
cancer risk (see Dr. Diamond’s review in this special issue), strong, specific evidence of the 
importance of selenoproteins/selenoenzymes to cancer risk/mortality is provided by 
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epidemiological data from cohorts identified by functional polymorphisms in selenoprotein 
genes, particularly at nutritional levels of intake.  Such epidemiological studies are described 
below and summarised in Tables 1 and 2 [25-39].     
 
Cytosolic glutathione peroxidase, GPx1  
Glutathione peroxidases protect cells against oxidative damage by reducing hydrogen 
peroxide and a wide range of organic peroxides with reduced glutathione [40].   A number of 
recent studies have reported a link between cancer risk and polymorphisms in the GPx1 gene 
at Pro198Leu (rs1050450) (see Table 1) [22,24,26,28,31,33,34].  Such a link might be 
explained by a genotype effect on enzyme activity [22,28].  For example, the GPX1 Leu 
allele has been found to be less responsive than the Pro allele to stimulation of GPx1 enzyme 
activity by selenium supplementation [22]. 
 
Bladder: Possession of the GPx1 Leu198 allele appears to confer an increased risk of bladder 
cancer [26].  In 213 Japanese patients, the Pro/Leu genotype was significantly associated with 
bladder cancer when compared with the Pro/Pro genotype (adjusted OR 2.63, 95% CI 1.45 to 
4.75, p = 0.001).  The effect of genotype on risk was similar for advanced prostate cancer 
(tumour stage Ta-1 vs T2-4, OR 2.58, 95% CI 1.07 to 6.18, P = 0.034).   
 An interaction exists between this gene and that for manganese superoxide dismutase 
(SOD2), the scavenger within the mitochondria that converts superoxide to hydrogen 
peroxide.  A single nucleotide polymorphism Val9Ala (rs4880) (more often, and hereinafter 
described as Val16Ala), in the SOD2 gene affects the secondary structure of the 
mitochondrial import sequence of the superoxide dismutase protein such that the Ala16 
variant is imported more efficiently into the mitochondrial matrix, resulting in higher enzyme 
activity [41].   Individuals with at least one SOD2-Ala16 allele (Ala16+) therefore generate 
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more active superoxide dismutase, and therefore more hydrogen peroxide, than those 
homozygous for the Val16 variant.  Hydrogen peroxide has been shown to promote the 
neoplastic transformation of urothelial cells [42], and to induce the matrix metalloproteinases 
required for tumour invasion [43,44].  As there is no catalase in mitochondria [45], the 
hydrogen peroxide that does not diffuse out must be removed by GPx1, with an efficiency 
that presumably varies by genotype, providing a rationale for the interaction between the two 
genes.  While there was no effect on bladder-cancer risk of the SOD2 polymorphism by itself, 
in SOD2-Ala16+ men, the risk associated with the Pro/Leu GPx1 genotype increased by a 
factor of 2.4 (OR 6.31, 95% CI 1.28 to 31.24, P = 0.024). 
 
Breast: The Leu/Leu genotype of the GPx1 Pro198Leu polymorphism was found to be 
almost twice as common in DNA from breast-cancer tissue as in DNA from cancer-free 
individuals while the Pro/Leu genotype was underrepresented, suggesting an involvement of 
GPx1 in breast cancer risk [22].  However, results from five epidemiological studies that 
investigated the effect of this polymorphism on breast-cancer risk have been inconsistent as 
outlined below.   
 In a nested Danish case-control study of 377 cases and 377 controls, carriers of the 
variant Leu-allele had a 1.43-times (95% CI 1.07 to 1.92) higher risk of breast cancer 
compared with non-carriers [28].  By contrast, in a Canadian case-control study of 399 cases 
of incident, invasive breast cancer and 372 controls, no association between breast cancer and 
the GPx1 Pro198Leu polymorphism was found [27].  Similarly, there was no evidence that 
the variant GPx1 genotype was associated with an increased risk of breast cancer in the Long 
Island Breast Cancer Study Project of 1,038 cases and 1,088 controls, except in nulliparous 
Leu homozygotes who had increased risk (OR 2.12, 95% CI 1.01-4.48) compared with 
parous Pro/Pro women [29].  Interestingly, though no association was observed between the 
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polymorphism and breast-cancer risk in the prospective Nurses’ Health Study, where 1323 
women with breast cancer were compared with 1910 controls [30], an increased risk of breast 
cancer (OR 1.87, 95% CI 1.09-3.19) was observed in Leu homozygotes who were also 
homozygous for the Ala16 genotype of SOD2 [31], a SNP allele already shown to raise the 
risk of bladder cancer [26].   
 
Lung: Four studies have looked at the association between the Pro198Leu polymorphism and 
the risk of lung cancer [24,32,33,46].  Compared to Pro homozygotes, two studies – in 
Finland and Korea – found a significantly increased risk of lung cancer in Leu hetero-
/homozygotes [24,32], while a small US study found a significantly-increased risk in never-
smoker Leu hetero-/homozygotes (only 13 cases), though a significantly-decreased risk was 
found in elderly smokers [46].  However, in the fourth study, carried out in Denmark, 
Leu/Leu homozygosity was associated with decreased risk [33].  The authors of the Danish 
study were themselves surprised by their result since they had previously shown that the 
variant Leu-allele was associated with a significant, although moderate, 5% lower erythrocyte 
GPx1 enzyme activity per allele [28].  They have suggested that the apparently-protective 
effect of the Leu-allele of the GPx1 polymorphism may be caused by a co-segregating 
functional polymorphism in another gene in the same region of the genome and not by the 
GPx1 polymorphism per se [33] though this explanation does not sit well with the fact that 
the Leu allele appears to increase risk in other studies and in other types of cancer.       
 
Prostate: In the context of the above results, it is perhaps surprising that an overall protective 
effect of the variant GPx1 Leu allele was found on prostate cancer risk in 82 prostate cancer 
cases and 123 control individuals in FYROM [34].  It is however somewhat suspicious that 
while heterozygous carriers of the variant Leu allele had a significantly lower risk of prostate 
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cancer compared with Pro homozygotes (OR 0.38, 95% CI 0.20 to 0.75, P = 0.004), Leu 
homozygotes had a non-significant and lesser reduction in risk.  No significant differences in 
erythrocyte GPx activity by genotype were found in the healthy control group of 90 subjects.  
In our own case-control study (2213 cases/controls) in Swedish men, we found no effect of 
the Pro198Leu polymorphism on prostate-cancer risk [Cooper ML, Adami HO, Grönberg H, 
Wiklund F, Green FR, Rayman MP, unpublished data].   
 
Other cancers: Loss of heterozygosity at GPx1 occurs in a significant percentage of 
colorectal (42%) and other cancers suggesting that GPx1 or other tightly linked genes might 
be involved in cancer etiology [47,48].  However in a study of 166 cases with 
adenocarcinoma, 974 with adenomas and 397 controls recruited from the Norwegian cohort 
NORCCAP, no associations were found between the GPx Pro198Leu polymorphism and risk 
of colorectal adenomas or carcinomas [49].  Similarly no associations were found between 
the GPx Pro198Leu polymorphism and risk of basal-cell carcinoma [50].   
 
 
Phospholipid glutathione peroxidase, GPx4  
GPx4 removes membrane-bound phospholipid hydroperoxides inhibiting lipoxygenases and 
affecting leukotriene biosynthesis, cell growth, apoptosis and inflammation [51,52]. 
 
Breast cancer: Though no effect of the GPx4 C718T polymorphism was found on the risk of 
developing breast cancer, carriage of the T allele was found to be associated with mortality in 
a UK study of ten antioxidant defence genes in 4470 breast cancer cases (see Table 2) [35].  
The most significant results were for two correlated SNPs in GPx4.  The rare (T) allele of the 
GPx4 C718T was associated with an increased risk of death, with a hazard ratio of 1.27 (95% 
Selenoproteins and human health 
 12 
CI, 1.13 to 1.43) per rare allele carried.  The frequency of the T allele is 0.46 in the UK 
population with 21% of women being T homozygotes.  These data provide strong support for 
the hypothesis that a common variant of GPx4 is associated with poor prognosis after a 
diagnosis of breast cancer.   
 
Colorectal cancer: A GPx4 C718T polymorphism (rs713041) which is known to be 
functional [52,53], has been shown to be linked to colorectal cancer risk in a pilot study (see 
Table 2) [36].  Carriage of the T allele appears to be protective in contrast to its effect on 
breast-cancer mortality.   
 
 
15kDa selenoprotein, Sep15  
The 15kDa selenoprotein (Sep15) is located in the endoplasmic reticulum (ER).  It is believed 
to be a thioldisulfide isomerase involved in disulfide bond formation in the ER that 
contributes to the quality control of protein folding [54].  Evidence suggests that Sep 15 is 
required for apoptosis and that its loss is associated with malignancy [54].   
 Sep15 is expressed at high levels in normal liver and prostate but at reduced levels in 
the corresponding malignant organs [55].  The Sep15 gene lies on chromosome 1p22.3 at a 
locus commonly deleted or mutated in human cancers [23,56] giving rise to expectations that 
this selenoprotein might be important to cancer risk.  Two SNPs at positions 811 (C/T) and 
1125 (G/A) that are in strong allelic association have been studied in the 3′-UTR of the Sep15 
gene: G/A1125 lies within a functional SECIS element [23].   The T811-A1125 variant was 
more effective in supporting UGA read-through than the C811-G1125 variant, but was less 
responsive to the addition of Se to the culture medium [21,57].  Similarly, malignant 
mesothelioma cells with the A1125 variant of Sep15 were found to be less responsive to the 
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apoptotic and growth-inhibitory effects of Se than the G1125 variant [58].  Individuals 
possessing one or other of these haplotypes may therefore differ in the efficiency with which 
they can make Sep15 and in how well they can use dietary Se [23].  
 
Lung cancer: A case-control study of 325 lung cancer cases and 287 controls in a population 
of Polish smokers of low Se status (mean plasma Se in controls 53.3 ± 14.0 µg/L), showed an 
effect of Sep15 G/A1125 genotype that varied according to Se status (see Table 2 and Figure 
1) [37].  Among individuals of lower Se status (below 50 µg/L), the risk was higher for those 
with the AA genotype compared to those with the GG genotype (OR 1.42, 95% CI: 0.43–
4.42) whereas among those of higher Se status (above 50 µg/L), the opposite was the case 
(AA vs GG, OR 0.37, 95% CI: 0.12–1.17).  Though these effects on risk are non-significant, 
there was a general significant association between Se concentration and lung cancer risk for 
the GG, GA and AA genotypes, P values for the trends in risk being 0.038, 0.035 and 0.030, 
respectively.  The results of this study suggest that those with the AA genotype benefit most 
from increasing dietary Se (which does not accord with the results of the in vitro studies 
mentioned above).  For those with the GA or GG genotype – 93.7% of the control population 
– when plasma Se rises above 70 µg/L, the odds of developing lung cancer begin to increase.   
This observation accords with the meta-analysis of Se and lung cancer that showed that only 
subjects in the lower categories of Se exposure benefit from increased Se intake [59].  This 
Polish study is a nice illustration of the potential complexity of interactions between genotype 
and Se status and confirms a role for this selenoprotein in cancer risk.   
 
Prostate cancer: Though the frequency of the T811/A1125 haplotype is 0.25 in Caucasians 
and 0.57 in African Americans, who have a higher incidence of prostate cancer [21], no 
evidence for an effect of this polymorphism on prostate cancer risk has yet been reported.  In 
our own case-control study (2213 cases/controls) in Swedish men of relatively low Se status, 
Selenoproteins and human health 
 14 
we found no effect of the 811 (C/T) linked 1125 (G/A) polymorphism on prostate-cancer risk 
(see Table 2).  However, in men with PSA > 100 ng/ml, the risk of prostate cancer was 
significantly greater in T811-A1125 homo/heterozygotes than in C811-G1125 homozygotes 
[Cooper ML, Adami HO, Grönberg H, Wiklund F, Green FR, Rayman MP, unpublished 
data].   
 
Breast, head and neck tumours: Among African Americans (but not Caucasians), a 
difference in Sep15 allele frequencies was seen in DNA from breast or head and neck 
tumours and that from cancer-free controls though the authors suggest that this difference is 
likely to be due largely to loss of heterozygosity at the Sep15 locus [21,60].   
 
 
Thioredoxin reductase 1  
All living organisms have an important antioxidant defense system consisting of the 
selenoenzyme, thioredoxin reductase, thioredoxin and NADPH [61].  Thioredoxin reductase 
1 (TXNRD1) is involved in the regulation of transcription factors, growth control, protein-
DNA interaction, and in the reduction of nucleotides for DNA synthesis [62].  It is highly 
expressed in a number of tumour tissues [38,62].   
 
Colorectal adenoma: TXNRD1 is abundantly expressed in the colon.  In a case-control study 
nested within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, cases with a 
left-sided advanced adenoma (n = 772) and matched controls (n = 777), screen-negative for 
polyps, were randomly selected from participants [38].  A significant 80% reduction in 
advanced colorectal adenoma risk was seen for carriers of the G allele of thioredoxin 
reductase 1 (TXNRD1) IVS1-181C>G (OR 0.20, 95% CI 0.07-0.55, P trend = 0.004) (see 
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Table 2).  A significant overall association with adenoma risk for TXNRD1 (global P 0.008) 
was observed.  However, the authors point out that it is possible that this SNP may not 
indicate an association with TXNRD1 but instead with E1A-like inhibitor of differentiation 3 
(EID3), a small gene nested within the intron of TXNRD1 [38,62].   
 
 
Selenoprotein P  
Selenoprotein P is a major selenoprotein in plasma, containing at least 40% of the total 
plasma Se [63].  Unlike any other selenoprotein, human selenoprotein P contains ten 
selenocysteine residues and it is believed to be responsible for the distribution of Se to body 
tissues [54].  It is also thought to be a scavenger of peroxynitrite [64]. 
 
Colorectal adenoma: While the human selenoprotein P gene (SEPP1) is abundantly 
expressed in normal colon mucosa, there is a significant reduction or loss of SEPP1 mRNA 
expression in colon cancers [65].  Since a number of SNPs have been identified in 
selenoprotein P, it was thought that some of those genetic variants might be associated with 
advanced colorectal adenoma, a colorectal-cancer precursor.  In the study described in the 
previous section, cases with a left-sided advanced adenoma and matched controls were 
randomly selected from participants in the Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial [38].   Three variants in SEPP1 (rs3797310, rs2972994, -4166), one of which 
was very rare (-4166), were significantly associated with advanced adenoma risk and a 
significant overall association with adenoma risk was observed for SEPP1 (global P = 0.02) 
(see Table 2).  SEPP1 SNPs rs3877899, rs6413428 and rs12055266 were not found to have 
an association with advanced colorectal adenoma.  
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Prostate: Normally, the SEPP1 gene is highly expressed in prostatic epithelium but it is 
down-regulated in a subset of human prostate tumours, mouse tumours and the androgen-
dependent (LNCaP) and androgen-independent (PC-3) prostate cancer cell lines [66].  Our 
group investigated the effect on prostate cancer risk of one of the SEPP1 SNPs already 
mentioned i.e. Ala234Thr (rs3877899), by genotyping DNA from 2,915 cases and 1,764 age-
matched controls from the population-based Prostate Cancer in Sweden (CAPS) study [39].  
This population had fairly low Se status i.e. mean (SD) = 76.0 (17.2) µg/L in plasma.  Cases 
were designated aggressive or non-aggressive at diagnosis by clinical criteria.   
 Although the SEPP1 Ala234 SNP allele is known to be associated with lower plasma 
selenoprotein P in men and this appears to reduce the concentration/activity of other 
antioxidant selenoproteins [67], by itself, this SNP did not affect prostate-cancer risk in our 
study (see Table 2).  However, men homozygous for SEPP1-Ala234 who also carried a 
SOD2-Ala16 allele (already discussed above) had a significantly higher risk of prostate 
cancer (OR 1.43, 95% CI 1.17 to 1.76) and advanced prostate cancer (OR 1.60, 95% CI 1.22 
to 2.09) than those who were SOD2-Val16 homozygotes (see Table 2) (interaction, prostate 
cancer P=0.05, advanced prostate cancer P=0.01).  The interaction was even stronger in ever-
smokers i.e. men homozygous for SEPP1-Ala234 who also carried a SOD2-Ala16 allele had 
almost double the risk of prostate cancer (OR 1.97, 95%CI 1.33 to 2.91; interaction P=0.001).  
The explanation for these results may relate to the fact that carriers of SOD2-Ala16 are 
known to produce more mitochondrial hydrogen peroxide as explained above [41] that if not 
removed, will promote prostate tumor-cell proliferation and migration [43,44,68,69].  In a 
low Se environment, male SEPP1-Ala234 homozygotes have lower plasma SEPP1 [67], thus 
limiting the transport of Se to the prostate for the production of GPx that could remove 
hydrogen peroxide [39].  As we have postulated that the mechanism by which these 
polymorphisms have their combined effect is oxidative-stress related, the greater strength of 
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the interaction in smokers than in the study as a whole, despite smaller numbers, might be 
explained by an exacerbation of oxidative stress in ever-smokers.   
 It is important to note that the joint effect of these polymorphisms was stronger for 
advanced prostate cancer than for all prostate cancer in line with other epidemiological 
studies where the effect of Se on localised and advanced prostate cancer was analysed 
separately [70-72].  As it is advanced prostate cancer that kills, this is an important finding. 
 
 
Summary of the evidence on involvement of selenoproteins in cancer risk from 
selenoprotein polymorphisms 
It is difficult to draw clear conclusions from some of the SNP evidence, as summarised in 
Tables 1 and 2, on the effect of selenoproteins on cancer risk.  With regard to the GPx1 
Pro198Leu polymorphism, some studies, notably that on bladder cancer [26], have shown an 
allele effect on GPx activity while others have not.  Some authors have suggested that these 
disparities might be explained if the change in GPx activity were to be caused by another 
polymorphism that co-segregates with the studied polymorphism [28].  Interestingly, though 
only one study showed a significant effect of carriage of the Leu allele on breast cancer risk 
[28], increased risk was observed in Leu homozygotes who were also homozygous for SOD2 
16Ala [31], as was the case for bladder cancer [26], implying that the risk associated with this 
polymorphism is affected by other genotypes and perhaps other environmental factors as 
well.  This is an illustration of the fact that cancer is a multifactorial complex disease and a 
combination of factors – not just a single polymorphism – is generally required to cause 
disease.  It is also possible that some of the discrepancies noted above may relate to differing 
Se status between populations investigated.  The fact that development of colorectal, breast 
and head and neck tumours is linked with loss of heterozygosity at GPx1 suggests that loss of 
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protective GPx1 activity may increase cancer risk.  Loss of heterozygosity in Sep15 also 
occurs in breast or head and neck tumours, again suggesting that ability to make this 
selenoprotein may be important in reducing risk.   
 Though there are many fewer studies that have investigated associations between 
polymorphisms in GPx4, Sep15, TXNRD1 and SEPP1 and cancer, significant effects have 
been found for the GPx4 C718T polymorphism on risk of death from breast cancer, for three 
SNPs in SEPP1 and one in TXNRD1 on the risk of advanced colorectal adenoma, and for the 
Ala234Thr SEPP1 polymorphism in men of relatively low Se status who carry a SOD2-
Ala16 allele on the risk of prostate cancer.   
 As a word of warning, however, it is possible that genetic variants in other genes at or 
near the loci of the selenoprotein polymorphisms under study might co-segregate, 
contributing to the effects observed.   All of the genetic variants that might contribute to such 
an effect must therefore be identified before disease risk can be definitely attributed to a 
particular selenoprotein polymorphism.   Nonetheless, on the face of it, it seems probable 
from epidemiological studies that have studied selenoprotein polymorphisms that the 
selenoproteins GPx1, GPx4, Sep15, TXNRD1 and SEPP1 are relevant to the cancer process.   
 Importantly, what has emerged from this analysis is that interactions between 
selenoprotein genes and genes in associated pathways (e.g. mitochondrial superoxide 
dismutase) can together influence risk, where neither might do so separately.  It is a fact that 
genome-wide association studies (GWAS), so much favoured by funding bodies at the 
moment, have generally not been powered to pick up such interactions, so real effects may be 
missed using that fashionable approach.  However, meta-analyses are now underway 
combining individual GWAS, and these may reveal more gene:gene interactions in the future. 
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Insights from case-control, prospective cohort studies and randomised controlled trials 
on possible involvement of selenoproteins in cancer prevention 
By examining the relationship between cancer risk and Se status, it may be possible to draw 
some speculative inferences about the likely involvement of selenoproteins in cancer risk, 
given that we have some idea of the plasma Se concentrations at which certain selenoproteins 
are likely to be optimised.  We know, for instance, that the mean plasma Se concentration 
needed to maximize plasma glutathione peroxidase (GPx3) activity is around 92 µg/L [5].  
This is generally believed to be sufficient to optimise the activity/concentration of other 
selenoproteins, with the exception of selenoprotein P which is known to be saturated at a 
plasma level of 125 µg/L [73].  GPx3 and selenoprotein P are down-regulated in prostate 
cancer and their importance to prostate-cancer risk [39] and metastasis [74] has recently been 
demonstrated, probably on account of their antioxidative and Se-transport functions.  Using 
epidemiological studies of prostate cancer in which plasma/serum Se have been measured as 
examples, let us attempt to see if their results can be explained by invoking the involvement 
of these selenoproteins.   
 For cohort studies, if these selenoproteins are involved, one might only expect to see 
an effect on risk of prostate cancer when the concentrations in the cohort range from below, 
to above, the level needed to optimise the activity of these enzymes.  Thus it is hardly 
surprising that no effect of Se on prostate-cancer risk was found in the EPIC study where the 
mean plasma Se concentrations were 70.6 µg/L (95% CI: 69.7, 71.5) and 71.9 µg/L (95% CI: 
71.0, 72.7) for cases and matched controls respectively [75,76].  These levels are insufficient 
to maximize the activity of GPx3 [5] (and that of other selenoenzymes) and are substantially 
below the level at which selenoprotein P is known to be saturated [73].  This would have 
severely limited the possibility of detecting a significant difference in prostate-cancer risk 
between cases and controls, assuming that these selenoproteins/selenoenzymes play an 
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important role [76].  The Baltimore Longitudinal Study of Aging [77] and the Physicians’ 
Health Study [72] show significant reductions in risk at plasma Se ≥ 108 µg/L (population 
range 82-182 µg/L) and ≥ 120 µg/L (population range 60-190 µg/L) respectively when 
compared to the lowest quantile.  These figures fit the theory that selenoproteins, and 
selenoprotein P in particular may affect prostate-cancer risk.  However, the study of Nomura 
and colleagues of Japanese-American men in Hawaii [70] shows a higher requirement i.e. ≥ 
147 µg/L, for significant reduction of risk than would fit with our theory.  A possible 
explanation may lie in the substantially different distribution of GPx1 genotypes in Japanese 
men than in men of European descent which may affect the interaction with Se status.   
 Results from the US Third National Health and Nutrition Examination Survey 
(NHANES III), suggest that increasing serum Se concentrations up to 130 µg/L are inversely 
associated with a reduced risk of all-cause and prostate-cancer mortality [78].  In fact, for 
prostate cancer the risk appears to fall quite sharply up to around 120 µg/L, after which it 
levels off before beginning to fall more slowly.  These observations are compatible with an 
effect of selenoproteins, notably selenoprotein P, on prostate-cancer mortality.  
 Turning to trial results, in the Nutritional Prevention of Cancer (NPC) trial, a daily 
200 µg Se supplement significantly reduced prostate-cancer risk only in those with initial 
plasma Se < 121 µg/L [79].  A later adjustment for the lower rate of PSA measurement in the 
Se group left only those with plasma levels < 106 µg/L still showing significant benefit from 
Se supplementation [79].  SELECT showed that giving 200 µg Se/d to a population of men of 
mean plasma Se 136 µg/L does not reduce the risk of localized prostate cancer [16].  
Unfortunately SELECT results tell us nothing about the effect of Se on risk of advanced 
disease – only 1.1% of cases were non-localised – nor on men of lower Se status.  Clearly 
while at least one third of NPC men did not have optimal selenoprotein P or even GPx 
concentration/activity, this was not true of SELECT men, all of whose selenoproteins were 
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likely to have been optimised.  Therefore if selenoproteins (rather than methyl selenol) are 
important in cancer prevention, no effect would have been seen in SELECT, as was indeed 
the case.  Such a trial conducted in Europe where Se status is substantially lower might have 
shown a very different outcome. 
 Indeed once Se intake is such as to optimise all selenoproteins (one assumes at a 
plasma Se concentration somewhere in the region of 120 µg/L) there appears to be no 
justification for giving additional Se, as it may increase disease risk.  There was a non-
significant increased risk of cancer in NPC participants in the highest tertile (baseline plasma 
Se >121.6 µg/L) and a significantly-increased risk of squamous cell carcinoma in those with 
baseline plasma Se in the top two tertiles [19,80].  In addition, further analysis of NPC trial 
data has shown an increased risk of self-reported Type-2 diabetes in those supplemented with 
Se, though the effect was significant only in those in the top tertile of plasma Se at baseline 
[81].  Furthermore, SELECT has reported a trend toward increased Type-2 diabetes incidence 
in participants receiving 200 µg/d Se alone [16].  Hence the advisability of supplementing 
individuals of already-replete status (say 120-125 µg/L or more) [73] with Se must be 
seriously questioned.   
 The above speculative analysis has largely ignored the effect of individual differences 
in Se requirements resulting from selenoprotein polymorphisms and other stressors [82] 
though this is clearly a factor to be considered.  However, it does suggest that optimising the 
activity/concentration of at least some selenoproteins, including selenoprotein P, can reduce 
prostate cancer risk. 
 
 
CONCLUSION 
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The evidence presented above goes some way to show how epidemiology can contribute to 
our understanding of the role of selenoproteins in health.  Selenoprotein genotype-specific 
effects are the most enlightening but the totality of evidence currently implicates the 
selenoproteins GPx1, GPx4, SEPS1, Sep15, SEPP1 and TXNRD1 in conditions such as 
cardiovascular disease, pre-eclampsia and cancer.  Ideally, studies need to determine not only 
Se status, but genotype, both in selenoproteins and related pathways, when investigating 
disease risk, since, as we have seen, these are interacting factors.  The limitations of most 
GWAS carried out to date in detecting gene-gene interactions that affect disease risk need to 
be appreciated.  Future interventions need to be in populations or subsets of populations that 
may be predicted to benefit from Se supplementation, such as those of low Se status or with a 
particular selenoprotein genotype [39,83].   Furthermore, scientists with a deep understanding 
of the likely mechanisms by which selenoproteins and Se metabolites may act, not just 
epidemiologists and clinical trialists, need to be intimately involved in the design of future 
trials, if the large sums of money required for such trials are to be spent wisely. 
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Table 1. GPx1: Proline/Leucine SNP at codon 198, 3p21. Effect of 198 Leu allele on cancer risk (modified from ref [25]) 
 
No. Subjects Cancer 
 
Cases Controls 
SNP genotype 
vs Pro/Pro 
 
OR (95% CI) 
* = significant 
 
Location 
 
Comments 
 
Reference 
 
Bladder 
 
213 209 Pro/Leu 
+SOD2 V/A+A/Aa 
 
2.6  (1.5 - 4.8)* 
6.3  (1.3 - 31.2)* 
 
Japan 
 
Pro/Leu signif. assoc. with 
advanced tumor stage 
 
26 
 
Breast 
 
399 372 Pro/Leu  
Leu/Leu 
 
0.92  (0.68 - 1.24) 
0.77  (0.46 - 1.27) 
 
Canada 
 
Pre-and post- 
menopausal 
 
27 
Breast 
 
377 377 Pro/Leu + Leu/Leu 
 
1.43  (1.07 - 1.92)* 
 
Denmark 
 
Postmenopausal 
 
28 
Breast 
 
1038 1088 Pro/Leu 
Leu/Leu 
 
1.10  (0.92 - 1.32) 
1.06  (0.79 - 1.42) 
 
US Long Island Breast Cancer 
Study 
 
29 
Breast 
 
1229 
 
1629 Pro/Leu 
Leu/Leu 
 
0.91  (0.77 - 1.07) 
1.07  (0.82 - 1.40) 
 
US Nurses’ Health Study 
 
30 
Breast 
 
1262 
 
1533 Pro/Leu + SOD2 A/Aa 
Leu/Leu +SOD2 A/Aa 
 
1.01 (0.83 -1.23) 
1.87 (1.09 - 3.19)* 
 
US Nurses’ Health Study 
 
31 
Lung 
 
315 315 Pro/Leu 
Leu/Leu 
 
1.8  (1.2 - 2.8)* 
2.3  (1.3 - 3.8)* 
 
Finland 
 
 24 
Lung 
 
200 200 Pro/Leu & Leu/Leu  
 
2.29 
 
Korea 
 
Article in Korean, no CIs in 
abstract 
 
32 
Lung 
 
432 798 Leu/Leu 
 
0.60 (0.35 - 1.05) 
 
Denmark 
 
 33 
Prostate 
 
82 123 
 
Pro/Leu 
Leu/Leu 
 
0.38 (0.20-0.75)* 
0.61 (0.27-1.40) 
 
FYROM Would expect stronger effect 
in Leu/Leu; small study 
 
34 
Prostate 
 
1433 
 
780 Pro/Leu 
Leu/Leu 
 
1.07 (0.89-1.29) 
0.93 (0.69-1.26) 
 
Sweden 
 
CAPS study 
 
Cooper et al. 
unpublished 
 
a SOD2 A/A = SOD2-Ala16Ala; SOD2 V/A= SOD2-Val16Ala; SOD2 V/V= SOD2-Val16Val 
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Table 2. Effect of Selenoprotein SNPs on Cancer Risk or Mortality (modified from ref [25]) 
 
No. Subjects Selenoprotein 
SNP 
 
Cancer 
Cases Controls 
Comparison 
 
OR (95% CI) 
 
Location 
 
Comments 
 
Reference 
 
GPx4  
C718T 
rs713041 
Breast 569 
deaths 
3901 T allele vs CC  1.27 (1.13-1.43)* per T 
allele carried  
UK   
 
Association of T allele with mortality in 
4470 breast cancer cases  
35  
 
 Colorectal 252 
 
187 CT+ TT vs CC  0.60 (0.37-0.96)* UK Carriage of T allele protective 36 
 Prostate 
 
1438 
 
790 
 
CT+TT vs CC 
 
1.01 (0.91-1.32) 
 
Sweden CAPS study 
 
Cooper et al. 
unpublished 
 
Sep15  
G1125A linked 
C811T  
 
Lung 
 
325     
smokers  
 
287 
smokers 
 
AA vs GG 
AA vs GG 
 
1.42 (0.43-4.42)  
0.37 (0.17-1.17)  
 
 
Poland 
 
 
 
Below 50 µg/L Se 
Above 50 µg/L Se 
37 
 
G1125A linked 
C811T 
 
Prostate 
 
1419 
318 
 
781 
781 
 
CG/TA+TA/TA vs 
CG/CG 
 
1.03(0.86-1.24) 
1.38 (1.05-1.83)* 
 
Sweden 
 
CAPS study 
Men with PSA>100 
Incr risk if TA homo/hererozygotes 
 
Cooper et al. 
unpublished 
 
TRR 
TXNRD1 IVS1-
181C>G 
rs35009941 
 
 
Advanced 
colorectal 
adenoma 
 
 
772 
 
 
777 
 
 
GC+GG vs CC 
 
 
0.20 (0.07-0.55)* 
 
 
US 
 
Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial  
Carriage of G allele protective 
 
378 
 
SEPP1 
rs3797310 
rs2972994 
-4166  
rs3877899 
 
Advanced 
colorectal 
adenoma 
 
 
 
746 
750 
749 
752 
 
762 
764 
763 
766 
 
 
AA vs GG 
CT vs CC  
CG vs CC  
AG vs GG 
AA vs GG 
 
1.53 (1.05-2.22)* 
0.73 (0.57-0.92)*  
P trend = 0.002*  
0.99 (0.79-1.24) 
0.98 (0.61-1.56) 
 
US 
 
 
 
 
 
 
Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial 
 
 
 
38 
 
 
 
rs3877899 
(Ala234Thr 
= G234A) 
 
Prostate 
 
2975 
 
2149 
 
AG vs GG 
AA vs GG 
GG + SOD2 V/A+A/A 
vs GG + SOD2 V/Va 
0.94 (0.82-1.07) 
1.09 (0.83-1.42) 
1.43 (1.17-1.76) 
 
Sweden 
 
CAPS study 
 
39 
 
a SOD2 A/A = SOD2-Ala16Ala; SOD2 V/A= SOD2-Val16Ala; SOD2 V/V= SOD2-Val16Val
a SOD2 A/A = SOD2-Ala16Ala; SOD2 V/A= SOD2-Val16Ala; SOD2 V/V= SOD2-Val16Val 
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Figure Legend 
 
Fig. 1 Joint effect of plasma Se concentration and Sep15 1125G/A polymorphism for lung 
cancer development.  Test for trends in Sep15 genotypes: P = 0.038 for GG, P = 0.035 for 
GA, P = 0.030 for AA.  Test for trend differences: AA vs. GG: P = 0.049, AA vs. GA: P = 
0.025 (reproduced with permission from reference [37]). 
